Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560010 · ClinicalTrials.gov registry record · Phase 4
TXA in Anticoagulated Patients Study
A Phase 4 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT04560010 is a Phase 4 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 17 participants.
The verdict
NCT04560010, a Phase 4 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a randomized, single-blind, single-center study comparing calculated total blood loss, surgical drain output and hematoma formation in anticoagulated patients who receive 2 doses of Tranexamic Acid (TXA) versus control group undergoing anatomical and reverse total shoulder arthroplasty (TSA). Patients will be randomized to either receive 2 doses of IV TXA, first dose prior to surgical incision and second dose given 3 hours later or to the control group, where no TXA will be administered.
Interventions
- DRUG Tranexamic Acid Injection (TXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2023-03-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04560010
The ClinicalTrials.gov registry entry for NCT04560010 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tranexamic Acid Injection (TXA) is the first listed.
NCT04560010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04560010 about?
NCT04560010 is a clinical study titled "TXA in Anticoagulated Patients Study". This is a randomized, single-blind, single-center study comparing calculated total blood loss, surgical drain output and hematoma formation in anticoagulated patients who receive 2 doses of Tranexamic Acid (TXA) versus control group undergoing anatomical and reverse total shoulder arthroplasty (TSA)...
What is the current status of trial NCT04560010?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2020-10-06. Estimated completion is 2023-03-11.
What interventions are being tested in trial NCT04560010?
The interventions under investigation include: Tranexamic Acid Injection (TXA) (DRUG).
Who is sponsoring clinical trial NCT04560010?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.